SNY
Pipeline
Oral selective ROCK2 inhibitor (Rezurock). Approved for chronic graft-versus-host disease (cGVHD) after at least two prior lines of systemic therapy.
Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins.
Taxane chemotherapy that stabilizes microtubules and arrests mitosis. Used in breast, prostate, NSCLC, head and neck, and gastric cancers.
Anti-IL-4Rα monoclonal antibody (Dupixent) that blocks both IL-4 and IL-13 signaling. Approved in atopic dermatitis, asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and prurigo nodularis.
QFITLIA is a double-stranded siRNA that causes degradation of AT messenger RNA (mRNA) through RNA interference, reducing plasma AT levels.
Gaucher disease is characterized by a deficiency of β-glucocerebrosidase activity, which results in accumulation of glucocerebroside in various tissues including liver, spleen, and bone marrow.
Intravenous immunoglobulin: pooled human polyclonal IgG used as immunomodulator/replacement therapy. Standard of care in CIDP, multifocal motor neuropathy, ITP, and primary immunodeficiency.
Migalastat is a pharmacological chaperone that reversibly binds to the active site of the alpha-galactosidase A (alpha-Gal A) protein (encoded by the galactosidase alpha gene, GLA ), which is deficient in Fabry disease.
Oral synthetic corticosteroid used as anti-inflammatory and immunosuppressant. Backbone in lymphoma regimens (R-CHOP, BEACOPP) and supportive care.
Oral reversible covalent BTK inhibitor (Sanofi). Phase 3 in immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia, and chronic spontaneous urticaria.
Teplizumab-mzwv binds to CD3 (a cell surface antigen present on T lymphocytes) and delays the onset of Stage 3 T1D in adult and pediatric patients aged 1 year and older with Stage 2 T1D.
Teriflunomide, an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis.
Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential.
Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite.
Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite.
Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intracellular enzyme) is then formed and the phosphatase activity of calcineurin is inhibited.
Belantamab mafodotin‑blmf is an antibody‑drug conjugate (ADC). The antibody component is an afucosylated IgG1 directed against BCMA, a protein expressed on normal B lymphocytes and multiple myeloma cells.
Anti-VEGF-A monoclonal antibody (Avastin) that inhibits tumor angiogenesis. Approved for colorectal, ovarian, breast, glioblastoma, and other solid tumors.
Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome.
Chimeric anti-EGFR monoclonal antibody (Erbitux) that blocks EGFR signaling and triggers ADCC. Approved in metastatic colorectal cancer (KRAS wild-type) and head and neck cancer.
Synthetic corticosteroid widely used as anti-inflammatory and immunosuppressant. In oncology, used in multiple myeloma regimens and as supportive care for chemotherapy-induced nausea/edema.
Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro products. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Anti-CTLA-4 monoclonal antibody (Yervoy) that releases T-cell inhibition early in immune activation. Approved in melanoma, RCC, MSI-H colorectal, and other cancers, often combined with nivolumab.
Anti-CD38 monoclonal antibody (Sarclisa). Approved in relapsed/refractory multiple myeloma in combination with pomalidomide+dexamethasone or carfilzomib+dexamethasone.
Oral immunomodulatory drug (Revlimid) that recruits IKZF1/IKZF3 to cereblon for degradation. Standard in multiple myeloma, MDS, and follicular lymphoma.
The cysteinyl leukotrienes (LTC 4 , LTD 4 , LTE 4 ) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils.
Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite.
Anti-PD-1 monoclonal antibody (Opdivo) that blocks the PD-1 checkpoint. Approved across melanoma, NSCLC, RCC, head and neck, hepatocellular, and other cancers.
Pomalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of pomalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex.